1. Home
  2. THC vs NBIX Comparison

THC vs NBIX Comparison

Compare THC & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenet Healthcare Corporation

THC

Tenet Healthcare Corporation

HOLD

Current Price

$266.88

Market Cap

17.8B

Sector

Health Care

ML Signal

HOLD

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

HOLD

Current Price

$154.16

Market Cap

15.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
THC
NBIX
Founded
1967
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.8B
15.5B
IPO Year
1994
1996

Fundamental Metrics

Financial Performance
Metric
THC
NBIX
Price
$266.88
$154.16
Analyst Decision
Buy
Strong Buy
Analyst Count
21
22
Target Price
$237.90
$180.91
AVG Volume (30 Days)
779.7K
1.4M
Earning Date
04-30-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
41.95
EPS
17.81
3.30
Revenue
$18,479,000,000.00
$161,626,000.00
Revenue This Year
$4.36
$24.73
Revenue Next Year
$1.89
$13.14
P/E Ratio
$15.03
$47.25
Revenue Growth
0.91
977.51
52 Week Low
$157.58
$122.14
52 Week High
$283.05
$186.12

Technical Indicators

Market Signals
Indicator
THC
NBIX
Relative Strength Index (RSI) 58.84 42.55
Support Level $183.92 $152.67
Resistance Level N/A $161.29
Average True Range (ATR) 6.87 3.72
MACD -2.55 0.28
Stochastic Oscillator 37.70 41.35

Price Performance

Historical Comparison
THC
NBIX

About THC Tenet Healthcare Corporation

Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (50 as of December 2025) and hundreds of ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Share on Social Networks: